Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children.
The aim of this study was to compare self-reported immediate post-vaccination pain and safety of Priorix versus RORVax in 4- to 6-year-old children receiving their second dose of MMR vaccine, using the Faces Pain Scale-Revised (FPS-R), a validated self-report pain scale recommended by the French National Accreditation Agency and Health Evaluation. A total of 620 children from 28 French pediatricians completed all study procedures. Immediate post-vaccination pain was reported by 17.8% of the subjects in Priorix group (N=309) and by 44.7% of the subjects in RORVax group (N=311) [OR=3.7; P<0.001]. Parents' pain scores correlated significantly with children's scores. The reduction of immediate pain incidence in Priorix group persisted over the 4 post-vaccination days. This study, using a validated self-assessment pain scale, confirmed previous data showing a significantly lower incidence of immediate post-vaccination pain with Priorix as compared to RORVax.
Wood
C
C
Unité de Traitement de la Douleur, Hôpital Robert Debré, 48, Boulevard Sérurier, 75019 Paris, France. chantal.wood@rdb.ap-hop-paris.fr
von Baeyer
C L
CL
Bourrillon
A
A
Dejos-Conant
V
V
Clyti
N
N
Abitbol
V
V
D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D015337:Multicenter Studies as Topic; D010146:Pain / Q000209:etiology*; D010147:Pain Measurement / Q000379:methods; D002666:Psychology, Child; D012449:Safety; D014611:Vaccination / Q000009:adverse effects
D022542:Measles-Mumps-Rubella Vaccine